Comparative Diagnostic Performance of CA125, HE4 and Recorded ROMA Scores in Ovarian Malignancy: A Retrospective Thai Regional Ubon Ratchathani Cancer Hospital Cohort
Aims: To describe the diagnostic performance of CA125, HE4, and recorded ROMA scores against final histopathology in a 402-record regional cancer-hospital cohort, and to assess the implications of risk-group, stage, and hereditary-risk subgroup analyses. Methods: This retrospective study examined 402 records dated 2020–2025 from a regional Thai cancer hospital, using the linked patient-level workbook and the source statistical report. The investigators confirmed that ethics approval permits using records from 2020–2026. Reported diagnostic estimates were compared with the workbook for data completeness and denominator consistency; unverified estimates were not treated as paired comparisons. Results: Among 402 records, 320 were coded malignant and 82 benign. After parsing comma-grouped numeric values and values annotated “Repeated” as the recorded numeric result, marker availability was CA125 n=402, HE4 n=192, and ROMA Pre and Post n=190 each. Recomputed AUCs were 0.9031 for CA125, 0.7033 for HE4, 0.7103 for ROMA Pre, and 0.8851 for ROMA Post. These estimates are marker-specific and do not establish incremental diagnostic value in a paired cohort. Conclusions: CA125 and recorded ROMA Post showed relatively high apparent discrimination in marker-specific analyses. Results are descriptive because the available marker cohorts differ, ROMA Pre/Post definitions are not independently validated, and subgroup stage coding requires adjudication. These findings do not demonstrate incremental diagnostic benefit.
Authors
- Surasak Wanram (ORCID: https://orcid.org/0000-0002-1866-0723)
- Thanita Parina
- Krittaya Somakasetrin
- Jiraon Karunpan
Publication Details
- Journal
- Preprints.org
- Published
- 2026-11-16
- DOI
- https://doi.org/10.20944/preprints202611.1569.v1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- preprint